598
|
Engrailed-2 (EN2)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.0001
|
Urine
|
21364037
|
808
|
Prostate Helth Index (phi)
|
Protein
|
Humans
|
Upregulated in Gleason Score ≥7
|
Prognostic
|
Gleason Score ≥7 and Gleason Score <7
|
p<0.0001
|
Blood
|
22078333
|
810
|
Prostate Helth Index (phi)
|
Protein
|
Humans
|
Upregulated with GS upgrading
|
Prognostic
|
Gleason sum upgrading from 6 to 7
|
p<0.0001
|
Blood
|
22078333
|
812
|
Prostate Helth Index (phi)
|
Protein
|
Humans
|
Upregulated in Tumor Stage pt3
|
Prognostic
|
pathological stage pt2 Vs pathological stage pt3
|
p<0.0001
|
Blood
|
22078333
|
909
|
Prostate Health Index (phi)
|
Protein
|
Humans
|
Upreregulated in PCa
|
Diagnostic
|
PCa VS No PCa group; PCa Vs HGPIN group
|
p< 0.001
|
Serum
|
22542564
|
964
|
Soluble interleukin-6 Receptor (sIL-6R)
|
Protein
|
Humans
|
Upregulated in higher Gleason Score (Without Gleason Score Upgrading: 65.62±23.87 Vs With Gleason Score Upgrading: 94.63±33.31)
|
Prognostic
|
Gleason Score Upgrading Vs No Gleason Score Uprading
|
p=0.024
|
Serum
|
22866141
|
965
|
Soluble interleukin-6 Receptor / Interleukin-6 ((sIL-6R/IL-6)
|
Protein
|
Humans
|
Upregulated in higher Gleason Score (Without Gleason Score Upgrading: 9.23±5.78 Vs With Gleason Score Upgrading: 15.61±4.94)
|
Prognostic
|
Gleason Score Upgrading Vs No Gleason Score Uprading
|
p=0.011
|
Serum
|
22866141
|
1027
|
Carbonic Anhydrase I
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCA Vs Healthy Controls
|
p = 0.022
|
Plasma
|
23213568
|
1028
|
PSA + Carbonic Anhydrase I
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCA Vs Healthy Controls
|
p = 0.022
|
Plasma
|
23213568
|
1046
|
Hemoglobin
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (all stages) vs. non-cancerous conditions
|
p < 0.05
|
Blood
|
23356551
|
1047
|
Prostate Specific Antigen (PSA)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
PC (all stages) vs. non-cancerous conditions
|
p < 0.05
|
Serum
|
23356551
|
1048
|
blood urea nitrogen (BUN)
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (all stages) vs. non-cancerous conditions
|
p < 0.05
|
Blood
|
23356551
|
1049
|
Prostate biopsy clinical decision rule (PBCDR): (HGB+ Age+ PSA+ RBC+Hematuria+ Creatinine+ Black (Ethnicity) + Albumin+ MCV)
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (all stages) vs. non-cancerous conditions
|
p < 0.05
|
Tissue
|
23356551
|
1050
|
Prostate biopsy clinical decision rule (PBCDR): (HGB+ RBC+ Creatinine+ PSA+ Age+ MCV+ Black (ethnicity))
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis)
|
p < 0.05
|
Tissue
|
23356551
|
1051
|
Hemoglobin
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis)
|
p < 0.001
|
Blood
|
23356551
|
1052
|
Hematuria
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis)
|
p < 0.05
|
Blood
|
23356551
|
1053
|
RBC
|
Others
|
Humans
|
NA
|
Diagnostic
|
PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis)
|
p < 0.05
|
Blood
|
23356551
|
1054
|
Prostate Specific Antigen (PSA)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis)
|
p < 0.001
|
Serum
|
23356551
|
1103
|
Apolipoprotein B
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.01
|
Serum
|
23582881
|
1104
|
Biotinidase
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p= 0.041
|
Serum
|
23582881
|
1105
|
Cell adhesion molecule 1
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p= 0.046
|
Serum
|
23582881
|
1106
|
Complement factor H
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p= 0.025
|
Serum
|
23582881
|
1107
|
Ceruloplasmin
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.041
|
Serum
|
23582881
|
1108
|
Carboxypeptidase M
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.001
|
Serum
|
23582881
|
1109
|
Intercellular adhesion molecule 1
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.041
|
Serum
|
23582881
|
1110
|
Galectin-3-binding protein
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.009
|
Serum
|
23582881
|
1111
|
Serum paraoxonase/arylesterase 1
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.011
|
Serum
|
23582881
|
1112
|
Poliovirus receptor-related protein 1
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.046
|
Serum
|
23582881
|
1113
|
Thrombospondin-1
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.022
|
Serum
|
23582881
|
1114
|
Transmembrane 9 superfamily member 3
|
Protein
|
Humans
|
Upregulated in Progression Free Survival
|
Prognostic
|
Progression Free Survival (PFS) at 12 weeks
|
p = 0.037
|
Serum
|
23582881
|
1121
|
Asporin; Cartilage oligomeric matrix Protein (COMP); Versican; EMILIN 3;
|
Protein
|
Humans
|
Upregulated in Agressive Prostate Cancer (Fold Change); [Asporin (2.14 fold); Cartilage oligomeric matrix Protein (COMP) (100 fold) ; Versican (100 fold) ; EMILIN 3 ( 6 fold);
|
Prognostic
|
Agressive Vs Non Agressive Prostate Cancer
|
Asporin (p=0.00016) ; Cartilage oligomeric matrix Protein (COMP) (p = 0.00228) ; Versican ( 0.03367) ; EMILIN 3 (0.04983);
|
Tissue
|
23716368
|
1122
|
Acid ceramidase
|
Protein
|
Humans
|
Downregulated in Agressive Prostate Cancer 0.18 Fold
|
Prognostic
|
Agressive Vs Non Agressive Prostate Cancer
|
p = 0.04983
|
Tissue
|
23716368
|
1124
|
β-CTX (β-isomer of carboxiterminal telopeptide of collagen I)
|
Protein
|
Humans
|
NA
|
Predictive
|
Survival Vs No Survival after treatment with zoledronic acid
|
p = 0.0049
|
Serum
|
23722472
|
1125
|
P1NP (aminoterminal propeptide of procollagen I)
|
Protein
|
Humans
|
NA
|
Predictive
|
Survival Vs No Survival after treatment with zoledronic acid
|
p = 0.0139
|
Serum
|
23722472
|
1127
|
Aminoadipic acid
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1128
|
Cerebronic acid
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1129
|
Gluconic acid
|
Metabolites
|
Humans
|
Downregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1130
|
Glycerophosphoethanol-amine
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1131
|
2-Hydroxybehenic acid
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1132
|
Isopentenyl pyrophosphate
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1133
|
Maltotriose
|
Metabolites
|
Humans
|
Downregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1134
|
7-Methylguanine
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1135
|
Tricosanoic acid
|
Metabolites
|
Humans
|
Upregulated in Prostate Cancer
|
Diagnostic
|
Malignant Vs Non Malignant
|
p<0.0001
|
Tissue
|
23737455
|
1136
|
Aminoadipic acid
|
Metabolites
|
Humans
|
Increased in Patients with Recurrence
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p =0.031
|
Tissue
|
23737455
|
1137
|
Gluconic acid
|
Metabolites
|
Humans
|
Decreased in Patients with Recurrence
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p =0.036
|
Tissue
|
23737455
|
1138
|
Maltotriose
|
Metabolites
|
Humans
|
Decreased in Patients with Recurrence
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p =0.006
|
Tissue
|
23737455
|
1139
|
Aminoadipic acid
|
Metabolites
|
Humans
|
Increased in Patients with Recurrence
|
Prognostic
|
Recurrence Free Survival Vs No Recurrence Free Survival
|
p =0.048
|
Tissue
|
23737455
|
1148
|
C-Reactive Protein (CRP)
|
Protein
|
Humans
|
Higher levels associated with shorter biochemical failure-free survival (Both for patients with Post- radical Prostatectomy and Definitive Radiotherapy)
|
Prognostic
|
Biochemical Failure Free survival
|
p = 0.009
|
Serum
|
23818401
|
1150
|
1,5-anhydroglucitol; 10-heptaadecenoate (17:1n7); 10-nonadecenoate (19:1n9); ; 15-HETE; 1-arachidonoylglycerophosphoethanolamine; 1- arachidonoylglycerophosphoinositol; 1-arachidoylglycerophosphocholine; 1-eicosadienoylglycerophosphocholine; 1-heptadecanoylglycerophosphocholine; 1-heptadecanoylglycerophosphoethanolamine; 1-linoleoylglycerophosphocholine; 1-linoleoylglycerophosphoethanolamine; 1-myristoylglycerophosphocholine; 1-oleoylglycerol; 1-oleoylglycerophosphocholine; 1-oleoylglycerophosphoethanolamine; 1-oleoylglycerophosphoinositol; 1-oleoylglycerophosphoserine; 1-palmitoleoylglycerophosphocholine; 1-palmitoleoylglycerophosphoethanolamine; 1-palmitoylglycerol; 1-palmitoylglycerophosphocholine; 1-palmitoylglycerophosphoethanolamine 1-palmitoylglycerophosphoinositol; 1-palmitoylplasmenylethanolamine; 1-stearoylglycerol; 1-stearoylglycerophosphocholine; 1-stearoylglycerophosphoethanolamine; 1-stearoylglycerophosphoglycerol; 1-stearoylglycerophosphoinositol; 2-aminoadipate; 2-aminobutyrate; 2-arachidonoylglycerophosphocholine; 2-arachidonoylglycerophosphoethanolamine; 2-docosahexaenoylglycerophosphoethanolamine; 2-hydroxybutyrate; 2-hydroxyglutarate; 2-hydroxypalmitate; 2-hydroxystearate; 2-linoleoylglycerophosphocholine; 2-linoleoylglycerophosphoethanolamine; 2-methylbutyrylcarnitine; 2-oleoylglycerophosphocholine; 2-oleoylglycerophosphoethanolamine; 2-oleoylglycerophosphoserine; 2-palmitoylglycerophosphocholine; 2-palmitoylglycerophosphoethanolamine; 2-stearoylglycerophosphocholine; 3-(4-hydroxyphenyl)lactate; 3-aminoisobutyrate; 3-carboxy-4-methyl-5-propyl-2-furanpropanoate; 3-dehydrocarnitine; 3-dephosphocoenzyme-A; 3-hydroxybutyrate; 3-hydroxyhippurate; 3-indoxyl-sulfate; 3-phosphoglycerate; 4-acetamidobutanoate; 4-androsten-3beta_17beta-diol-disulfate-1; 4-hydroxybutyrate; 4-hydroxyhippurate; 4-methyl-2-oxopentanoate; 5,6-dihydrouracil; 5-alpha-androstan-3beta_17beta-diol-disulfate 5-methylthioadenosine; 5-oxoproline; 6-sialyllactose; 6-sialyl-N-acetyllactosamine; 7-alpha-hydroxy-3-oxo-4-cholestenoate; acetylcarnitine; acetylcholine; Ac-Ser-Asp-Lys-Pro; adenine; adenosine; adenosine 5'-diphosphate; adenosine 5'-monophosphate; adenosine 5'-diphosphoribose; adenosine 5-triphosphate; adenylosuccinate; adrenate (22:4n6); agmatine; alanine; alanylleucine; alanylphenylalanine; alanyltyrosine; alpha-glutamylvaline; alpha-hydroxyisovalerate; alpha-tocopherol; androsterone sulfate; arabitol; arabonate; arachidonate (20:4n6); arginine; ascorbate; asparagine; aspartate; aspartylleucine; aspartylphenylalanine; beta-alanine; beta-hydroxyisovalerate; betaine; butyrylcarnitine; caffeine; caproate (6:0); caprylate (8:0); carnitine; catechol-sulfate; C-glycosyltryptophan; chiro-inositol; cholesterol; choline; choline phosphate; cis-aconitate; cis-vaccenate (18:1n7); citrate; citrulline; coenzyme-A; creatine; creatinine; cysteine; cysteine-glutathione-disulfide; cysteinylglycine; cystine; cytidine; cytidine 5'-diphosphocholine; cytidine 5'-monophosphate; dehydroisoandrosterone sulfate; deoxycarnitine; dihomo-linoleate (20:2n6); docosadienoate (22:2n6); docosahexaenoate (22:6n3); docosapentaenoate (22:5n3); docosapentaenoate (22:5n6); docosatrienoate (22:3n3); eicosapentaenoate (20:5n3); ergothioneine; erythritol; erythronate; ethanolamine; flavin adenine dinucleotide; fructose; fucose; fumarate; galactose; gamma-aminobutyrate; gamma-glutamylalanine; gamma-glutamylglutamate; gamma-glutamylglutamine; gamma-glutamylleucine; gamma-tocopherol; gluconate; glucose; glucose 6-phosphate; glucose 1-phosphate; glutamate; glutamate, gamma-methyl ester; glutamine; glutarate; glutarylcarnitine; glutathione, oxidized; glutathione, reduced; glycerate; glycerol; glycerol 2-phosphate; glycerol 3-phosphate; glycerophosphoethanolamine; glycerophosphorylcholine; glycine; glycochenodeoxycholate; glycylisoleucine; glycylleucine; glycylproline; glycyltyrosine; glycylvaline; guanine; guanosine; guanosine-5-monophosphate; hexanoylcarnitine; hippurate; histamine; histidine; hydroxyisovaleroyl-carnitine; hypotaurine; hypoxanthine; inosine; inositol-1-phosphate; Isobar: 15-methylpalmitate, 2-methylpalmitate; Isobar: alpha-linolenate, gamma-linolenate (18:3n3 18:3n6); Isobar: dihomo-linolenate (20:3n3, 20:3n6); Isobar: dimethylarginine (ADMA, SDMA); Isobar: eicosenoate (20:1n9, 20:1n11); Isobar: fructose-1,6-diphosphate, glucose-1,6-diphosphate, myo-inositol-1,4-diphosphate, myo-inositol-1,3-diphosphate; Isobar: 13-HODE, 9-HODE; isobutyrylcarnitine; isocitrate; isoleucine; isoleucylisoleucine; isoleucylserine; isovalerylcarnitine; kynurenine; lactate; laurate (12:0); leucine; leucylglutamate; leucylleucine; leucylphenylalanine; leucylserine; linoleate (18:2n6); lysine; malate; maltose; maltotetraose; maltotriose; mannitol; mannose; margarate (17:0); mead acid (20:3n9); methionine; methyl-alpha-glucopyranoside; methylphosphate; myo-inositol; myristate (14:0); myristoleate (14:1n5); myristoylcarnitine; N1-methylguanosine; N2-methylguanosine; N-acetylalanine; N-acetylaspartate; N-acetyl-aspartylglutamate; N-acetylgalactosamine; N-acetylglucosamine; N-acetylglutamate; N-acetylmethionine; N-acetylneuraminate; N-acetylputrescine; N-acetyltryptophan; nicotinamide; nicotinamide adenine dinucleotide, reduced; nicotinamide adenine dinucleotide; nicotinamide ribonucleotide; nicotinamide riboside; nonadecanoate (19:0); octanoylcarnitine; oleate (18:1n9); oleoylcarnitine; ophthalmate; ornithine; palmitate (16:0); palmitoleate (16:1n7); palmitoylcarnitine; palmitoyl sphingomyelin; pantothenate; p-cresol sulfate; phenol sulfate; phenylacetylglutamine; phenylalanine; phenylalanylalanine; phenylalanylaspartate; phenylalanylglutamate; phenylalanylleucine; phenyllactate; phosphate; phosphoethanolamine; pipecolate; piperine; pregnen-diol-disulfate; pro-hydroxy-pro-proline; propionylcarnitine; prostaglandin I2; pseudouridine; putrescine; pyridoxate; pyroglutamine; pyroglutamylvaline; pyruvate; quinate; ribitol; riboflavin; ribose; ribulose; S-adenosylhomocysteine; sarcosine; scyllo-inositoll; serine; serotonin; serylleucine; serylphenylalanine; S-methylcysteine; sorbitol; spermidine; spermine; sphingosine ; stearate (18:0); stearoylcarnitine; stearoyl sphingomyelin; succinate; succinylcarnitine; taurine; theobromine; threonine; threonylisoleucine; threonylleucine; threonylphenylalanine; thymol sulfate; tiglyl carnitine; trans-4-hydroxyproline; tryptophan; tryptophan betaine; tyrosine; tyrsoylleucine; uracil; urate; urea; uridine; uridine 5'-monophosphate; valerylcarnitine; valine; valylmethionine; valyltyrosine; VGAHAGEYGAEALER; xanthine; xanthosine; xylitol; xylonate; xylulose;
|
Metabolites
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.05
|
Tissue
|
23824564
|
1151
|
Histidine; Glycine; Alanine; Kynurenine; Glutamate; Glycerol 3-phosphate (G3P); Betaine; Pipecolate 2-methylbutyrylcarnitin; Isobar: 15-methylpalmitate; 2-methylpalmitate; Threonine; Cytidine 50-diphosphocholine; Valine; Myristoleate (14:1n5); S-adenosylhomocysteine (SAH); Phosphate; Choline; 2-aminobutyrate 2-hydroxypalmitate; Glycerol; Adenine; 2-hydroxystearate; Deoxycarnitine; Fumarate; Docosadienoate (22:2n6);
|
Metabolites
|
Humans
|
Increased with Upgraded Gleason Score
|
Prognostic
|
Gleason Score Upgrading [6 to 7 (3+4) to 7(4+3) to 8]
|
p<0.05
|
Tissue
|
23824564
|
1152
|
Adenosine 50 -diphosphate (ADP); Citrate; Palmitoyl-sphingomyelin;
|
Metabolites
|
Humans
|
Decreased with Upgraded Gleason Score
|
Prognostic
|
Gleason Score Upgrading [6 to 7 (3+4) to 7(4+3) to 8]
|
p<0.05
|
Tissue
|
23824564
|
1153
|
5,6-dihydrouracil +choline phosphate+ glycerol + methylpalmitate
|
Metabolites
|
Humans
|
Differentially Expressed
|
Prognostic
|
Organ Confined Vs Non Orgnan Confined
|
p<0.05
|
Tissue
|
23824564
|
1154
|
7-HOCA+ pregnen-diol disulfate +mannosyl tryptophan
|
Metabolites
|
Humans
|
Differentially Expressed
|
Prognostic
|
Progression Free Survival (5 years) Vs No Progression Free Survival (5 years)
|
p<0.05
|
Tissue
|
23824564
|
1156
|
Peptide ID: 3495; 3506; 3621; 3992; 4437; 4679; 4697; 5180; 6832; 7661; 8698; 9483; 9645; 10502; 11899; 12083; 13995; 14592; 15331; 18990; 19773]
|
Protein
|
Humans
|
Upregulated in PCa [mean(case)/mean(control)]: Downregulated in PCa [mean(control)/mean (case)]: []
|
Diagnostic
|
Prostate Cancer and Benign Prostatic Hyperplasia Vs inflammatory and healthy prostate
|
p< 0.0137
|
Plasma
|
23826311
|
1157
|
Peptide ID: [7098; 8863; 9673; 10706; 24050]
|
Protein
|
Humans
|
Downregulated in PCa [mean(control)/mean (case)]: [Peptide ID: [7098 (3.3 fold) ; 8863 (7.7 fold) ; 9673(73.1 fold) ; 10706 (124.8 fold) ; 24050( 11.1 fold)]
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p< 0.0027
|
Plasma
|
23826311
|
1158
|
21PP + 5PP
|
Protein
|
Humans
|
Differentially Expressed
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p=0.0001
|
Plasma
|
23826311
|
1159
|
Peptide ID: [1004; 2663; 5650; 7228; 9483; 9504; 10193; 10442; 10471; 10502; 17993]
|
Protein
|
Humans
|
Upregulated in PCa [mean(case)/mean(control)]: Downregulated in PCa [mean(control)/mean (case)]: []
|
Prognostic
|
Localised Vs Advanced Prostate Cancer
|
p=0.0055
|
Plasma
|
23826311
|
1176
|
Prostate Health Index (phi)
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No evidence of Maligancy
|
p <0.001
|
Serum
|
23861782
|
1206
|
Neuropeptideâ€Y (NPY)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs (Normal and BPH patients)
|
p = 0.0396
|
Plasma
|
23991666
|
1207
|
Neuropeptideâ€Y (NPY) + Prostate Specific Antigen (PSA)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs (Normal and BPH patients)
|
p = 0.0396
|
Plasma
|
23991666
|
1217
|
Cytochrome P450 family 24 subfamily A member 1 (CYP24A1)
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p = 0.03
|
Tissue
|
24081904
|
1242
|
iXip: [IgM] + [tPSA]
|
Protein
|
Humans
|
Upregulated in PCa [PCa: 0.467 ± 0.160; Controls: 0.314 ± 0.098]
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p <0.001
|
Serum
|
24240583
|
1247
|
Anterior gradient 2 [AGR2]
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p = 0.026
|
Urine
|
24251762
|
1420
|
Macrophage Colony Stimulating Factor (M-CSF)
|
Protein
|
Humans
|
Upregulated in PCa: (> 2 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.0001
|
Serum
|
24747338
|
1421
|
CC chemokine ligand 18 (CCL-18)
|
Protein
|
Humans
|
Upregulated in PCa: (> 2 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.0001
|
Serum
|
24747338
|
1422
|
Insulin-Like Growth Factor-Binding Protein 6 (IGFBP-6)
|
Protein
|
Humans
|
Upregulated in PCa: (> 2 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.0001
|
Serum
|
24747338
|
1423
|
Ttumor Necrosis Factor Receptor Superfamily Member 6 (TNFRSF6) [FAS/TNFRSF6]
|
Protein
|
Humans
|
Upregulated in PCa: (> 2 fold)
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.0001
|
Serum
|
24747338
|
1454
|
Prostate Health Index (phi)
|
Protein
|
Humans
|
Upregulated in PCa: [Prostate Volume ≤ 35: Negative Biopsy: 41.32 (31.30–64.23), Positive Biopsy: 64.93 (23.30–252.76) 36 ≤ Prostate Volume ≤ 50 : Negative Biopsy: 35.38 (20.69–49.80), PCa: 44.56 (21.88–132.72);Prostate Volume >50: 38.34 (19.23–72.63), PCa: 46.28 (24.33–80.34)]
|
Diagnostic
|
Negative Vs PCa (Segregated on the basis of Prostate Volume)
|
Prostate Volume ≤ 35:p= 0.001;36 ≤ Prostate Volume ≤ 50 : p= 0.011;Prostate Volume >50: 0.009
|
Serum
|
24978824
|
1455
|
N-terminal telopeptide of type I collagen (NTx)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Gleason Score
|
p< 0.001
|
Serum
|
24992524
|
1456
|
N-terminal telopeptide of type I collagen (NTx)
|
Protein
|
Humans
|
NA
|
Prognostic
|
Prostate Cancer Stage
|
p = 0.007
|
Serum
|
24992524
|
1561
|
Linoleic
|
Metabolites
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Cancer
|
p=0.04
|
Tissue
|
8922296
|
1594
|
Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA]
|
Protein
|
Humans
|
Upregulated in GS ≤ 7
|
Prognostic
|
Gleason Score <7 and Gleason Score ≤7
|
p<0.0001
|
Blood
|
25454615
|
1666
|
tPSA
|
Protein
|
Humans
|
Upregulated in PCa Cell Lines
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25847734
|
1676
|
tPSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1677
|
fPSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1678
|
p2PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1679
|
%fPSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1680
|
%p2PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1681
|
PHI
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1682
|
tPSA+ fPSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1683
|
tPSA+ %fPSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1684
|
fPSA + p2PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1685
|
%fPSA + %p2PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1686
|
PSA + %fPSA + %p2PSA
|
Protein
|
Humans
|
NA
|
Prognostic
|
High Grade PCa Vs Low Grade PCa
|
NA
|
Serum
|
25847734
|
1687
|
TIMP1 (Tissue Inhibitor Of Metalloproteinase 1)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
PCa Vs No PCa
|
p=0.003
|
Serum
|
25967040
|
1688
|
sE-Cadherin
|
Protein
|
Humans
|
NA
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25967040
|
1689
|
Clusterin
|
Protein
|
Humans
|
NA
|
Diagnostic
|
PCa Vs No PCa
|
p=0.004
|
Serum
|
25967040
|
1690
|
MMP9
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa Vs No PCa
|
p<0.001
|
Serum
|
25967040
|
1691
|
Galectin
|
Protein
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
PCa Vs No PCa
|
p=0.01
|
Serum
|
25967040
|
1692
|
sE-Cadherin
|
Protein
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Gleason Pattern 3 Vs 4 Vs 5
|
p=0.02
|
Serum
|
25967040
|
1693
|
sE-Cadherin
|
Protein
|
Humans
|
Downregulated in PCa
|
Prognostic
|
Gleason Upgrade Vs No Gleason Upgrade
|
p=0.03
|
Serum
|
25967040
|
1774
|
Small HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00070
|
Blood
|
30352818
|
1775
|
VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00056
|
Blood
|
30352818
|
1776
|
Cholesterol esters in medium LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00058
|
Blood
|
30352818
|
1777
|
Cholesterol esters to total lipids ratio in medium LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00062
|
Blood
|
30352818
|
1778
|
Cholesterol esters in small HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00002
|
Blood
|
30352818
|
1779
|
Cholesterol esters to total lipids ratio in small HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00111
|
Blood
|
30352818
|
1780
|
Cholesterol esters in small LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00107
|
Blood
|
30352818
|
1781
|
Cholesterol esters to total lipids ratio in small LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00139
|
Blood
|
30352818
|
1782
|
Free cholesterol in IDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00057
|
Blood
|
30352818
|
1783
|
Free cholesterol in large LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00080
|
Blood
|
30352818
|
1784
|
Free cholesterol in medium LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00060
|
Blood
|
30352818
|
1785
|
Free cholesterol to total lipids ratio in medium HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00055
|
Blood
|
30352818
|
1786
|
Total cholesterol in HDL3
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00109
|
Blood
|
30352818
|
1787
|
Total cholesterol in medium LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00095
|
Blood
|
30352818
|
1788
|
Total cholesterol to total lipids ratio in medium LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00105
|
Blood
|
30352818
|
1789
|
Total cholesterol in small HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.00001
|
Blood
|
30352818
|
1790
|
Total cholesterol to total lipids ratio in small HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00106
|
Blood
|
30352818
|
1791
|
Total cholesterol in small LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00132
|
Blood
|
30352818
|
1792
|
Total cholesterol to total lipids ratio in small LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00107
|
Blood
|
30352818
|
1793
|
Total cholesterol to total lipids ratio in small VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00105
|
Blood
|
30352818
|
1794
|
Phospholipids in IDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00092
|
Blood
|
30352818
|
1795
|
Phospholipids to total lipids ratio in medium LDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00046
|
Blood
|
30352818
|
1796
|
Phospholipids to total lipids ratio in medium VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.00001
|
Blood
|
30352818
|
1797
|
Phospholipids in very small VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00103
|
Blood
|
30352818
|
1798
|
Phospholipids to total lipids ratio in very small VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00013
|
Blood
|
30352818
|
1799
|
Total lipids in small HDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00035
|
Blood
|
30352818
|
1800
|
Triglycerides to total lipids ratio in medium VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00064
|
Blood
|
30352818
|
1801
|
Triglycerides to total lipids ratio small VLDL
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00055
|
Blood
|
30352818
|
1802
|
Ratio of omega-6 Fatty Acids to total Fatty Acids
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00080
|
Blood
|
30352818
|
1803
|
Ratio of saturated Fatty acids to total Fatty acids
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00006
|
Blood
|
30352818
|
1804
|
Isoleucine
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00008
|
Blood
|
30352818
|
1805
|
Leucine
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00027
|
Blood
|
30352818
|
1806
|
Tyrosine
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00003
|
Blood
|
30352818
|
1807
|
Valine
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00139
|
Blood
|
30352818
|
1808
|
Albumin
|
Metabolites
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.00065
|
Blood
|
30352818
|
1809
|
AMACR (Alpha methylacyl A coenzyme racemase)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
NA
|
Semen
|
30337219
|
1810
|
AMACR (Alpha methylacyl A coenzyme racemase) + Age
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
NA
|
Semen
|
30337219
|
1811
|
PHI (Prostate Health Index)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
NA
|
Serum
|
30926382
|
1812
|
PHID (Prostate Health Index Density)
|
Protein
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
NA
|
Serum
|
30926382
|
1882
|
Keratin, type II cytoskeletal 2 epidermal; Serum amyloid Pâ€component;Keratin, type II cytoskeletal 1; Keratin, type I cytoskeletal 9; Isoform 2 of Filamin A; Isoform 3 of Vitamin Dâ€binding protein; Ig kappa chain Vâ€II region Cum; soform 2 of Eukaryotic translation initiation 1.8 factor 2â€alpha kinase 4; Ig alphaâ€1 chain C region; Afamin;
|
Protein
|
Humans
|
Increased in Progression Free survival
|
Diagnostic
|
Prostate Cancer in African American Men Vs Normal African American Men
|
p<0.05
|
Serum
|
30623593
|
1883
|
Complement component C8 alpha chain; Apolipoprotein Aâ€I; Plasminogen; Complement component C7;Isoform 2 of Interâ€alphaâ€trypsin inhibitor heavy chain H4;Interâ€alphaâ€trypsin inhibitor heavy chain H1; Complement C1s subcomponent; Ig heavy chain Vâ€III region BRO; Ig gammaâ€2 chain C region; Ig gammaâ€3 chain C region;
|
Protein
|
Humans
|
Decreased in Progression Free Survival
|
Diagnostic
|
Prostate Cancer in African American Men Vs Normal African American Men
|
p<0.05
|
Serum
|
30623593
|
1884
|
Complement component C8 alpha chain; Apolipoprotein Aâ€I; Plasminogen; Complement component C7;Isoform 2 of Interâ€alphaâ€trypsin inhibitor heavy chain H4;Interâ€alphaâ€trypsin inhibitor heavy chain H1; Complement C1s subcomponent; Ig heavy chain Vâ€III region BRO; Ig gammaâ€2 chain C region; Ig gammaâ€3 chain C region;
|
Protein
|
Humans
|
Decreased in Overall Survival
|
Diagnostic
|
Prostate Cancer in Caucasian American Men Vs Normal Caucasian American Men
|
p<0.05
|
Serum
|
30623593
|
1885
|
SCOâ€spondin; Complement component C7;Isoform 2 of Ankyrin repeat and SOCS box protein 18; Gelsolin; Serum amyloid Pâ€component; g heavy chain Vâ€I region V35; Complement C1q subcomponent subunit C; Complement component C8 alpha chain; Isoform 2 of Filamin A; Inter-alpha trypsin inhibitor heavy chain H2;
|
Protein
|
Humans
|
Upregulated in PCa (Keratin, type II cytoskeletal 2 epidermal (64 fold); Serum amyloid Pâ€component (39 fold) ;Keratin, type II cytoskeletal 1 (13 fod) ; Keratin, type I cytoskeletal 9 (12 fold) ; Isoform 2 of Filamin A (2.6 fold) ; Isoform 3 of Vitamin Dâ€binding protein (2.4 fold); Ig kappa chain Vâ€II region Cum (2.4 fold) ; Isoform 2 of Eukaryotic translation initiation 1.8 factor 2â€alpha kinase 4 (1.8 fold) ; Ig alphaâ€1 chain C region (1.7 fold) ; Afamin (1.5 fold);
|
Diagnostic
|
Prostate Cancer in Caucasian American Men Vs Normal Caucasian American Men
|
p<0.05
|
Serum
|
30623593
|
1886
|
Isoform 2 of Eukaryotic translation initiation factor 2â€alpha kinase 4; Keratin type I cytoskeletal 10; SCO†spondin; Serum amyloid Pâ€component; Apolipoprotein(a); Keratin, type I cytoskeletal 9; Ig kappa chain Vâ€IV region; Isoform 2 of Filamin A; Keratin, type II cytoskeletal 1; Keratin, type II cytoskeletal 2 epidermal;
|
Protein
|
Humans
|
Downregulated in PCa [Complement component C8 alpha chain (0.07 fold); Apolipoprotein Aâ€I (0.04 fold); Plasminogen (0.08 fold); Complement component C7 (0.1 fold); Isoform 2 of Interâ€alphaâ€trypsin inhibitor heavy chain H4 (0.2 fold); Interâ€alphaâ€trypsin inhibitor heavy chain H1 (0.2 fold); Complement C1s subcomponent (0.2 fold); Ig heavy chain Vâ€III region BRO (0.2 fold); Ig gammaâ€2 chain C region (0.2 fold); Ig gammaâ€3 chain C region (0.2 fold);]
|
Diagnostic
|
African American men with PCa (PAA) Vs Caucasian men with PCa (PCC)
|
p<0.05
|
Serum
|
30623593
|
1887
|
Ig heavy chain Vâ€III region BRO; Alphaâ€1â€antitrypsin; Plasminogen (0.1†fold); Ig heavy chain Vâ€III region TIL, Hemopexin; Afamin; Interâ€alphaâ€trypsin inhibitor heavy chain H1; Protein AMBP; Alphaâ€1Bâ€glycoprotein; Complement component C8 alpha chain;
|
Protein
|
Humans
|
Upregulated in PCa [Alphaâ€1â€acid glycoprotein 1 (13.6â€fold); Alphaâ€1Bâ€glycoprotein (11.6â€fold); von Willebrand factor (5.0â€fold); Ig heavy chain Vâ€II region NEWM (6.0â€fold); Ig heavy chain Vâ€III region BRO (5.7â€fold); Afamin (5.4â€fold); Apolipoprotein Aâ€I (4.9â€fold); Isoform 3 of Vitamin Dâ€binding protein (4.3â€fold); Complement C1r subcomponent (4.3†fold); Angiotensinogen (4.1â€fold);
|
Diagnostic
|
African American men with PCa (PAA) Vs Caucasian men with PCa (PCC)
|
p<0.05
|
Serum
|
30623593
|
1888
|
4-(3,4-dihydro-2,2,4-trimethyl-2H-1-benzopyran-4-yl)-phenol; Estradiol; Ethyl à-hydroxymyristate trisiloxane; 1-(2,4-Dimethylphenyl)-3-(tetrahydrofuryl-2)propane; 2-amino-Imidazole-5-carboxylic acid; 1,1,3,3,5,5,7,7,9,9-decamethyl-pentasiloxane; 1,1,1,5,5,5-hexamethyl-3,3-bis[(trimethylsilyl)oxy]-Trisiloxane; Phthalic acid, bis(7-methyloctyl) ester; 4-Nitro-4’-chlorodiphenylsulfoxide; 1-Propylpentachlorotriphosphazene; 2,6-di-t-butyl-4-hydroxymethylene-2,3,5,6-detetrahydrocyclohexanone
|
Metabolites
|
Humans
|
Downregulated in PCa [SCOâ€spondin (0.1 fold); Complement component C7 (0.1â€fold); Isoform 2 of Ankyrin repeat and SOCS box protein 18 (0.3â€fold); Gelsolin (0.3â€fold); Serum amyloid P-component (0.4â€fold); Ig heavy chain Vâ€I region V35 (0.5â€fold); Complement C1q subcomponent subunit C (0.5â€fold); Complement component C8 alpha chain (0.6â€fold); Isoform 2 of Filamin A (0.6â€fold); and Inter-alpha-trypsin inhibitor heavy chain H2 (0.7â€fold);]
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p<0.05
|
Urine
|
30853355
|